Additionally, the 36-month beta value for GMRE is 1.29. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for GMRE is 63.03M and currently, short sellers hold a 2.23% ratio of that float. The average trading volume of GMRE on February 28, 2025 was 498.30K shares.
GMRE) stock’s latest price update
Global Medical REIT Inc (NYSE: GMRE)’s stock price has gone rise by 4.30 in comparison to its previous close of 8.48, however, the company has experienced a 5.68% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-02-28 that REITs are highly attractive now due to stable or falling interest rates and low inflation, with many offering strong yields while being undervalued. This article identifies 27 REITs yielding at least 75 basis points above the no-risk rate on Treasuries, while selling at discounts of 20% or greater to their Target Fair Value. The list is then screened for dividend safety, to eliminate sucker yields, and for stable revenues, excluding those with flat or declining FFO/share.
GMRE’s Market Performance
Global Medical REIT Inc (GMRE) has seen a 5.68% rise in stock performance for the week, with a 12.96% gain in the past month and a -0.17% plunge in the past quarter. The volatility ratio for the week is 1.71%, and the volatility levels for the past 30 days are at 1.94% for GMRE. The simple moving average for the last 20 days is 8.09% for GMRE’s stock, with a simple moving average of 0.10% for the last 200 days.
Analysts’ Opinion of GMRE
Many brokerage firms have already submitted their reports for GMRE stocks, with Berenberg repeating the rating for GMRE by listing it as a “Buy.” The predicted price for GMRE in the upcoming period, according to Berenberg is $11.75 based on the research report published on October 18, 2024 of the previous year 2024.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see GMRE reach a price target of $12. The rating they have provided for GMRE stocks is “Buy” according to the report published on September 19th, 2024.
Robert W. Baird gave a rating of “Neutral” to GMRE, setting the target price at $9 in the report published on October 10th of the previous year.
GMRE Trading at 10.65% from the 50-Day Moving Average
After a stumble in the market that brought GMRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.51% of loss for the given period.
Volatility was left at 1.94%, however, over the last 30 days, the volatility rate increased by 1.71%, as shares surge +11.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.49% upper at present.
During the last 5 trading sessions, GMRE rose by +5.62%, which changed the moving average for the period of 200-days by -0.56% in comparison to the 20-day moving average, which settled at $8.18. In addition, Global Medical REIT Inc saw 14.57% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for GMRE
Current profitability levels for the company are sitting at:
- 0.36 for the present operating margin
- 0.64 for the gross margin
The net margin for Global Medical REIT Inc stands at 0.03. The total capital return value is set at 0.09. Equity return is now at value 0.77, with 0.35 for asset returns.
Based on Global Medical REIT Inc (GMRE), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at 0.11. The debt to equity ratio resting at 1.17. The interest coverage ratio of the stock is 1.63.
Currently, EBITDA for the company is 111.67 million with net debt to EBITDA at 6.26. When we switch over and look at the enterprise to sales, we see a ratio of 8.41. The receivables turnover for the company is 17.9for trailing twelve months and the total asset turnover is 0.12.
Conclusion
In conclusion, Global Medical REIT Inc (GMRE) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
